BIANCHI, Francesca
 Distribuzione geografica
Continente #
NA - Nord America 943
EU - Europa 476
AS - Asia 148
AF - Africa 44
SA - Sud America 1
Totale 1.612
Nazione #
US - Stati Uniti d'America 942
IT - Italia 143
UA - Ucraina 75
IE - Irlanda 62
SE - Svezia 60
CN - Cina 56
SG - Singapore 50
DE - Germania 36
TR - Turchia 24
CI - Costa d'Avorio 22
DK - Danimarca 22
MA - Marocco 22
GB - Regno Unito 19
FI - Finlandia 15
FR - Francia 15
BE - Belgio 14
KR - Corea 14
NL - Olanda 9
IN - India 3
AT - Austria 2
CA - Canada 1
CO - Colombia 1
HR - Croazia 1
PL - Polonia 1
RO - Romania 1
RU - Federazione Russa 1
TJ - Tagikistan 1
Totale 1.612
Città #
Chandler 175
Jacksonville 84
Ashburn 69
Boardman 69
Ann Arbor 68
Fairfield 66
Dublin 57
New York 41
Woodbridge 39
Wilmington 34
Singapore 28
Houston 27
Cambridge 24
Abidjan 22
Ancona 22
Seattle 22
Lawrence 20
Princeton 20
Des Moines 18
San Mateo 18
Brussels 11
Centro 11
San Diego 11
Tolentino 11
Beijing 9
Turin 9
Cascina 5
Redmond 5
Cupra Marittima 4
Falconara Marittima 4
Ningbo 4
Xi'an 4
Guangzhou 3
Helsinki 3
London 3
Macerata 3
Norwalk 3
Shanghai 3
Washington 3
Wuhan 3
Amsterdam 2
Arzano 2
Citta 2
Clifton 2
Como 2
Los Angeles 2
Milan 2
Pune 2
Redwood City 2
Torre Del Greco 2
Vienna 2
Waanrode 2
Yiwu 2
Zibo 2
Ascoli Piceno 1
Bogotá 1
Burlington 1
Campogalliano 1
Cattolica 1
Chengdu 1
Dushanbe 1
Friesland 1
Grünwald 1
Hangzhou 1
Jiaxing 1
Kilburn 1
Liberty Lake 1
Limerick 1
Marche 1
Mondolfo 1
Osimo 1
Ottawa 1
Phoenix 1
Porto Sant'Elpidio 1
Prescot 1
Qingdao 1
Quanzhou 1
Saint Petersburg 1
San Jose 1
Seoul 1
Shenzhen 1
Trecastelli 1
Villa Verucchio 1
Warsaw 1
Waterloo 1
Weitang 1
Woodhall Spa 1
Wuxi 1
Totale 1.097
Nome #
'Secrets and lies'--the difficulties of communicating within families with inherited cancer syndromes. 95
Clinical impact of different exosomes’ protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapy 94
A missense germline mutation in exon 7 of the MSH2 gene in a HNPCC family from center-Italy. 92
Prognostic relevance of programmed cell death protein 1/programmed death-ligand 1 pathway in thymic malignancies with combined immunohistochemical and biomolecular approach 91
An intronic mutation in MLH1 associated with familial colon and breast cancer. 89
Assessing the pathogenicity of MLH1 missense mutations in patients with suspected hereditary nonpolyposis colorectal cancer: correlation with clinical, genetic and functional features. 87
Expression Profiling of Circulating Tumor Cells in Pancreatic Ductal Adenocarcinoma Patients: Biomarkers Predicting Overall Survival 85
Mutations of hMLH1 and hMSH2 in patients with suspected hereditary nonpolyposis colorectal cancer: correlation with microsatellite instability and abnormalities of mismatch repair protein expression. 82
A germline missense mutation in exon 3 of the MSH2 gene in a Lynch syndrome family: correlation with phenotype and localization assay 81
Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: Are all mutations equal? 80
BRCA-associated protein 1 (BAP1) and miR-31 combination predicts outcomes in epithelioid malignant pleural mesothelioma 78
Impact of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) single nucleotide polymorphisms on outcome in gastroenteropancreatic neuroendocrine neoplasms 72
MSH2 splice site mutation and endometrial cancer. 68
MSH2 missense mutations and HNPCC syndrome: pathogenicity assessment in a human expression system 65
Expectations and psychological issues before genetic counseling: analysis of distress determinant factors 64
Insulin-like Growth Factor (IGF) 1 and 2 help to predict disease outcome in GIST patients 63
Effectiveness of the CRCAPRO program in identifying patients suspected for HNPCC. 61
Beta-catenin gene analysis in oral squamous cell carcinoma. 58
KIT and PDGFR(alpha) mutations in 104 patients with gastrointestinal stromal tumors (GISTs): a population-based study. 52
Lynch syndrome-associated lung cancer: pitfalls of an immunotherapy-based treatment strategy in an unusual tumor type 51
1621P miRNA signature as early predictor of hyponatremia and survival in lung cancer: Preliminary results from the ISA retrospective study 46
miRNA signature as early predictor of hyponatremia and survival in lung cancer: preliminary results from the ISA retrospective study 32
null 31
Molecular Tumour Board (MTB): From Standard Therapy to Precision Medicine 21
BRCA mutations and gastrointestinal cancers: When to expect the unexpected? 8
Totale 1.646
Categoria #
all - tutte 9.119
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.119


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020105 0 0 0 0 25 3 16 3 19 3 10 26
2020/2021330 17 38 54 9 29 15 25 23 32 34 35 19
2021/2022182 5 36 3 3 20 11 8 12 19 20 12 33
2022/2023421 28 62 21 44 41 59 0 21 77 7 53 8
2023/2024251 30 7 17 22 40 54 2 3 1 3 3 69
2024/2025203 74 52 42 14 21 0 0 0 0 0 0 0
Totale 1.646